Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) Starts Presentation at 29th Annual Roth Conference
Zynerba Pharmaceuticals (NASDAQ: ZYNE) is a specialty pharmaceutical company that focuses on developing and commercializing proprietary synthetic cannabinoid therapeutics formulated for transdermal delivery. The company’s product candidates include ZYN002, which is in Phase I clinical trial for the treatment of refractory epilepsy, Fragile X syndrome, and osteoarthritis; and ZYN001 that is in preclinical stage for the treatment of fibromyalgia and peripheral neuropathic pain. For more information, visit the company’s website at www.zynerba.com. About CannabisNewsWire CannabisNewsWire (CNW) provides news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution…